Loading...
•
Sep 30
Fate Therapeutics Q3 2025 Earnings Report
Fate Therapeutics reported a net loss in Q3 2025 as operating expenses continued to exceed modest collaboration revenue.
Key Takeaways
The company posted a $32.3 million net loss on $1.7 million in revenue, maintaining focus on advancing its clinical pipeline and preserving a strong cash position.
Revenue for Q3 2025 was $1.7 million, derived from a preclinical collaboration with Ono Pharmaceutical.
Net loss for the quarter was $32.3 million, with operating expenses totaling $36.5 million.
Cash, cash equivalents, and investments totaled $225.7 million, supporting operations through year-end 2027.
Common shares outstanding reached 115.3 million, with additional pre-funded warrants and preferred shares issued.
Fate Therapeutics
Fate Therapeutics
Fate Therapeutics Revenue by Segment
Revenue by Segment
Collaboration Revenue
CapyFin.com Forward Guidance
Fate expects its $226M cash position to support operations through 2027 as it progresses clinical trials and initiates new IND-enabling activities.
Positive Outlook
- Cash and investments support runway through year-end 2027.
- Advancements in FT819 program with international trial site approvals.
- First patient treated in FT836 study with no adverse events.
- Ongoing enrollment and promising data in autoimmune and oncology trials.
- Appointment of experienced CFO to guide financial strategy.
Challenges Ahead
- Continued net losses due to high R&D and G&A expenses.
- Declining revenue YoY in collaborations.
- No approved therapies yet generating commercial revenue.
- Dependent on future successful IND filings and trial progress.
- Limited near-term catalysts for shareholder value realization.